Anniina Koski

发表

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy

A. Hemminki, A. Kanerva, Ilkka Liikanen, 2015, Oncoimmunology.

IMPROVING EFFICACY OF ADENOVIRAL CANCER GENE THERAPY

A. Koski, Anniina Koski, 2012 .

Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer.

R. Alemany, A. Hemminki, A. Kanerva, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders

K. Partanen, K. Jokivarsi, P. Soininen, 2014, International journal of cancer.

Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.

N. Linder, Riku Turkki, J. Lundin, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells

A. Ristimäki, A. Hemminki, K. Guse, 2009, The journal of gene medicine.

Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer

A. Hemminki, M. Siurala, Simona Bramante, 2016, Oncoimmunology.

Mutation of the Fiber Shaft Heparan Sulphate Binding Site of a 5/3 Chimeric Adenovirus Reduces Liver Tropism

A. Hemminki, A. Kanerva, A. Kipar, 2013, PloS one.

Effects of capsid‐modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer

M. Jokinen, A. Hemminki, S. Parviainen, 2012, International journal of cancer.

Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

K. Partanen, A. Hemminki, K. Guse, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.

A. Hemminki, V. Cerullo, M. Vähä-Koskela, 2012, Advances in cancer research.

Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.

A. Hemminki, V. Cerullo, M. Vähä-Koskela, 2012, Advances in cancer research.

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy

K. Partanen, N. Linder, Riku Turkki, 2015, Oncotarget.

Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

K. Partanen, A. Hemminki, S. Tähtinen, 2013, Clinical Cancer Research.

Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.

K. Partanen, A. Hemminki, V. Cerullo, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM‐CSF: Results in vitro, in rodents and in humans

D. Nettelbeck, A. Hemminki, Simona Bramante, 2015, International journal of cancer.

Serotype chimeric oncolytic adenovirus coding for GM‐CSF for treatment of sarcoma in rodents and humans

A. Hemminki, Simona Bramante, L. Vassilev, 2014, International journal of cancer.

Oncolytic adenovirus based on serotype 3

R. Desmond, A. Hemminki, K. Guse, 2011, Cancer Gene Therapy.

Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.

K. Partanen, A. Hemminki, Simona Bramante, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Oncolytic adenoviruses and certain chemotherapeutics can induce autophagy and immunogenic cancer cell death

K. Partanen, A. Hemminki, Simona Bramante, 2013 .

Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs.

A. Hemminki, M. Siurala, A. Kanerva, 2019, Human gene therapy.

T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.

N. Linder, Riku Turkki, J. Lundin, 2015, Molecular Therapy.

Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors.

J. Palmgren, K. Hemminki, A. Hemminki, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy.

K. Hemminki, A. Hemminki, A. Kanerva, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.

A. Hemminki, Simona Bramante, L. Vassilev, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients

A. Hemminki, S. Tähtinen, A. Kanerva, 2018, Oncotarget.

Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.

N. Linder, Riku Turkki, J. Lundin, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer.

K. Partanen, A. Hemminki, A. Koski, 2013, Human gene therapy.

Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy

A. Hemminki, A. Kanerva, Ilkka Liikanen, 2018, Molecular therapy oncolytics.